- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| Di | Apimeds Pharmaceuticals stärkt Management mit zwei neuen Führungskräften | - | Investing.com Deutsch | ||
| Di | Apimeds Pharmaceuticals adds two key executives to leadership team | 3 | Investing.com | ||
| 05.06. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.05. | Apimeds Pharmaceuticals US, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| 20.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.05. | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 498 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
| 12.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 119 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen | |
| 09.05. | Apimeds Pharmaceuticals starts trading at $4 per share in line with IPO pricing | 1 | Investing.com | ||
| 09.05. | Apimeds Pharmaceuticals startet Handel bei 4 US-Dollar je Aktie gemäß Börsengang-Preis | 2 | Investing.com Deutsch | ||
| 09.05. | Inflammation drug developer Apimeds Pharmaceuticals US prices IPO at $4.00, the low end of the range | 3 | Renaissance Capital | ||
| 05.05. | IPO Roundup: American Integrity Insurance, Apimeds Pharmaceuticals and more | 1 | Seeking Alpha | ||
| 02.05. | Apimeds Pharmaceuticals US, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 15.04. | Apimeds Pharmaceuticals US, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 15.04. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Preview: Apimeds Pharmaceuticals Us, Inc Set To IPO Tomorrow | 20 | Benzinga.com | ||
| 03.03. | Apimeds Pharmaceuticals US, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 20.02. | Apimeds Pharmaceuticals Us, Inc To Start Trading Tomorrow | 1 | Benzinga.com |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,200 | -16,85 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| QIAGEN | 41,050 | -0,86 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,540 | +11,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| BIONTECH | 93,70 | -1,00 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 57,50 | +2,68 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| ITEOS THERAPEUTICS | 10,300 | +0,29 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| SAB BIOTHERAPEUTICS | 2,950 | +4,98 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
| AVIDITY BIOSCIENCES | 34,920 | +3,50 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,230 | +2,41 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| 180 LIFE SCIENCES | 3,220 | +71,28 % | 180 Life Sciences beschleunigt Zuteilung von Aktienvergütungen für Führungskräfte | ||
| SUMMIT THERAPEUTICS | 26,630 | +1,64 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| REDHILL BIOPHARMA | 2,820 | +46,11 % | RedHill Biopharma Ltd.: RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease | The positive FDA feedback allows for:
A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium... ► Artikel lesen | |
| ABSCI | 3,570 | +14,24 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
| BRUKER | 30,700 | -12,03 % | Bruker-Aktie bricht nach Umsatzwarnung für Q2 ein | ||
| VERVE THERAPEUTICS | 10,990 | +0,69 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly |
APIMEDS PHARMACEUTICALS US INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,270 (+14,96 %) liegt der Kurs bei 2,075 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.